Sign in

Philip Wagenheim

Director at Immunome
Board

About Philip Wagenheim

Philip Wagenheim, age 54, has served on Immunome’s Board since December 2017 and was interim Chief Executive Officer from January to March 2017. He holds a B.B.A. from the University of Miami and brings venture capital and financial expertise in life sciences through leadership roles at Broadband Capital entities and other companies .

Past Roles

OrganizationRoleTenureCommittees/Impact
Immunome, Inc.Interim Chief Executive OfficerJan 2017 – Mar 2017
Committed Capital Acquisition Corporation IISecretary, President, and DirectorApr 2014 – Jun 2017
Broadband Capital Management LLC and affiliatesVice Chairman and leadership rolesMar 2000 – presentFinancial/strategic leadership

External Roles

OrganizationRoleTenure/StatusNotes
Broadband Capital Partners, LLCManaging MemberApr 2016 – presentFinancial/investment role
Hydrobuilder Holdings LLC (private)DirectorDec 2020 – presentPrivate hydroponics company
Sacrilege Motors LLC (private)Chief Executive Officer2021 – presentAutomotive technology company

Board Governance

  • Board class/term: Class III; continuing in office until the 2026 annual meeting .
  • Committee assignments: None (no Audit, Compensation, or Nominating committee roles listed) .
  • Independence: The Board’s 2025 independence determination lists five independent directors (Barchas, Bienaimé, Boylan, Schafer, Swain); Mr. Wagenheim is not included in that independent group .
  • Attendance and engagement: In 2024, the Board held 8 meetings; Audit 4; Compensation 6; Nominating 4. No director attended fewer than 75% of the aggregate Board and relevant committee meetings; all current directors at the time attended the 2024 annual meeting .

Fixed Compensation (Director)

YearAnnual Cash Retainer ($)Committee Member Fees ($)Committee Chair Fees ($)Total Cash ($)
202440,000 0 (no committee roles) 0 (no chair roles) 40,000

Reference policy (2024): $40,000 annual director retainer; $7,500 Audit member; $5,000 Compensation member; $5,000 Nominating member; $15,000 Audit Chair; $10,000 Compensation Chair; $10,000 Nominating Chair .

Performance Compensation (Director)

YearEquity Grant TypeGrant-Date Fair Value ($)Options Outstanding as of 12/31/24 (#)
2024Stock options134,999 35,583
  • Vesting mechanics (policy): Annual non-employee director option grants are made after each annual meeting with an aggregate value of $135,000 and vest in equal quarterly installments over one year; initial director options (for new appointees post-Oct 27, 2023) vest quarterly over three years. Unvested director options accelerate on Change in Control if the director remains in service through the transaction .
  • Performance metrics: Director equity is time-vested; no performance-based metrics disclosed for director compensation .

Other Directorships & Interlocks

CategoryCompanyRoleNotes
Current public company boardsNo current public company directorships disclosed in the proxy biography
Private boards/rolesHydrobuilder Holdings LLCDirectorPrivate company
Private boards/rolesBroadband Capital Partners, LLCManaging MemberPrivate firm
Private company roleSacrilege Motors LLCCEOPrivate company

Expertise & Qualifications

  • Board states Mr. Wagenheim is qualified due to extensive venture capital experience in life sciences and financial expertise; B.B.A., University of Miami (1992) .

Equity Ownership

As ofCommon Shares OwnedOptions Exercisable within 60 DaysTotal Beneficial OwnershipOwnership %Notes
Feb 1, 2025406,147 32,749 438,896 <1% Options outstanding (total) 35,583 as of 12/31/24
  • Hedging/pledging: Company policy prohibits directors and employees from hedging and from purchasing on margin or pledging company stock as collateral .

Governance Assessment

  • Independence and committees: Mr. Wagenheim is not among directors the Board determined to be independent in 2025 and holds no committee assignments, which limits direct oversight roles via committees .
  • Attendance: Met the company’s attendance expectation (no director below 75% of meetings in 2024) .
  • Pay structure and alignment: 2024 non-employee director pay comprised $40,000 cash and $134,999 in stock options under a standardized policy, providing equity-based alignment; unvested options accelerate on Change in Control .
  • Ownership: Beneficially owns 438,896 shares (including 32,749 options exercisable within 60 days), aligning interests with shareholders; percentage of outstanding shares is less than 1% .
  • Related-party and conflicts: The proxy’s related-person transactions since January 1, 2023 list participants in the 2025 follow-on offering and 2023 PIPE; Mr. Wagenheim is not listed among the related parties in those transactions .
  • Controls and policies: Clawback/recoupment oversight sits with the Compensation Committee; hedging and pledging are prohibited by policy, supporting alignment and risk control .

RED FLAGS and Watch Items

  • Not listed as independent by the Board in 2025; investors focused on majority-independent boards and committee composition may view this as a governance consideration .
  • No current committee assignments or chair roles, which reduces direct committee-level influence over audit, compensation, and nominating oversight .
  • Director equity is time-vested rather than performance-based; while common for directors, it does not include explicit performance conditions .

No related-party transactions involving Mr. Wagenheim were disclosed for 2023–2025 in the proxy; continue monitoring future proxies and 8-Ks for any changes .